{"public_id":"cl_472f4d210c4c3db2802ee3b8bf08cf14","status":"active","superseded_by_public_id":null,"corpus_id":35926507,"text":"A reduction of at least two points in the Knodell necroinflammatory score occurred in 56% of patients receiving 100 mg lamivudine, 49% receiving 25 mg, and 25% receiving placebo.","confidence":0.99,"paper":{"corpus_id":35926507,"title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","url":"https://sah.borca.ai/papers/35926507"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.99,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0381ac05a061bb6764a0fadbb8a7ca5b","name":"Knodell necroinflammatory score","description":"A liver histology scoring system used to quantify necroinflammatory activity.","types":["score"],"url":"https://sah.borca.ai/concepts/co_0381ac05a061bb6764a0fadbb8a7ca5b"},{"public_id":"co_352ace11cc877b13e5a3c2741a5c3d0a","name":"placebo","description":"An inactive control treatment used for comparison in the trial.","types":["control"],"url":"https://sah.borca.ai/concepts/co_352ace11cc877b13e5a3c2741a5c3d0a"},{"public_id":"co_b87617beade29d4fca97a28c5b7c9ce8","name":"lamivudine","description":"An oral nucleoside analogue evaluated as a treatment for chronic hepatitis B.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_b87617beade29d4fca97a28c5b7c9ce8"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_472f4d210c4c3db2802ee3b8bf08cf14"}